Who are SGLT2 inhibitor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NBF, Bexagliflozin tablets, Dapagliflozin+ACEI treatment, Control Rx, Concomitant therapy 14 days, senfrol monotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sglt2-inhibitor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

SGLT2 inhibitor — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SGLT2 inhibitor (SGLT2 inhibitor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes, Cardiovascular, Nephrology.

marketed SGLT2 inhibitor SGLT2 (sodium-glucose cotransporter 2) Diabetes, Cardiovascular, Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

SGLT2 inhibitor (SGLT2 inhibitor) — University of Minnesota. SGLT2 inhibitors block sodium-glucose cotransporter 2 in the kidney, preventing glucose reabsorption and promoting urinary glucose excretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SGLT2 inhibitor TARGET	SGLT2 inhibitor	University of Minnesota	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
NBF	NBF	Universidad Complutense de Madrid	marketed	SGLT2 inhibitor	SGLT2
Bexagliflozin tablets	Bexagliflozin tablets	Theracos	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Dapagliflozin+ACEI treatment	Dapagliflozin+ACEI treatment	Children's Hospital of Fudan University	marketed	SGLT2 inhibitor + ACE inhibitor combination	SGLT2 and ACE
Control Rx	Control Rx	National and Kapodistrian University of Athens	marketed	SGLT2 inhibitor
Concomitant therapy 14 days	Concomitant therapy 14 days	Incheon St.Mary's Hospital	marketed	SGLT2 inhibitor	SGLT2
senfrol monotherapy	senfrol monotherapy	Peking University Third Hospital	marketed	SGLT2 inhibitor	SGLT2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
Takeda · 10 drugs in this class
Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
Hanmi Pharmaceutical Company Limited · 9 drugs in this class
Addpharma Inc. · 9 drugs in this class
GlaxoSmithKline · 7 drugs in this class
AO GENERIUM · 7 drugs in this class
Merck Sharp & Dohme LLC · 7 drugs in this class
Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SGLT2 inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/sglt2-inhibitor. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing